Venus Remedies Ltd. (BSE: 526953) is a Panchkula, Haryana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,929 Cr, it ranks #1,264 by market cap among the 6,197 Indian listed companies on FinBizNet, and #37 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,500.00 (as of 16 Nov 2026), the share price is 26.6% below its 52-week high of ₹2,044.30 and 239.6% above its 52-week low of ₹441.75. The share price is up 239.1% over one year and down 13.4% over three months.
| Current Price | ₹1,500.00 |
|---|---|
| Market Cap | ₹1,929 Cr |
| BSE Code | 526953 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 18.7 |
| Return on Equity | 16.78% |
| Return on Assets | 9.87% |
| 52-Week Range | ₹441.75 – ₹2,044.30 |
| 1-Year Price Change | +239.1% |
| 3-Month Price Change | -13.4% |
| Beta (1Y) | -0.23 |
| Dividend Yield | 0.70% |
| Headquarters | Panchkula, Haryana |
| Website | www.venusremedies.com |
| Revenue | ₹219 Cr |
|---|---|
| Net Profit | ₹26 Cr |
| Net Margin | 11.7% |
| EPS (Basic) | ₹19.19 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Venus Remedies Ltd. reported revenue of ₹219 Cr in Q2 FY27, up 13.5% from ₹193 Cr in Q2 FY26 and up 22.3% from ₹179 Cr in Q1 FY27. It posted a net profit of ₹26 Cr for the quarter, against a net profit of ₹20 Cr in Q2 FY26 (up 27.4%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹132 Cr (Q1 FY26) to ₹259 Cr (Q4 FY26). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹219 Cr | ₹26 Cr | 11.7% |
| Q1 FY27 | ₹179 Cr | ₹23 Cr | 12.8% |
| Q4 FY26 | ₹259 Cr | ₹47 Cr | 18.3% |
| Q3 FY26 | ₹180 Cr | ₹26 Cr | 14.2% |
| Q2 FY26 | ₹193 Cr | ₹20 Cr | 10.4% |
| Q1 FY26 | ₹132 Cr | ₹10 Cr | 7.3% |
| Q4 FY25 | ₹195 Cr | ₹21 Cr | 10.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 41.76% of Venus Remedies Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Venus Remedies Limited engages in the pharmaceutical business in India and internationally. It is involved in the research and development of solutions focusing on antimicrobial resistance and oncology. The company also offers analgesic, analgesic and antipyretic, antibiotic, anticoagulant, antiemetic, antiviral, cardiovascular, disinfectant and antiseptic, gastro therapy, hepatoprotective, hormones (steroid), immunostimulating agent, iron supplements, muscle relaxant, neurology, oncology, and solvent products, as well as herbal medicine. The company was incorporated in 1989 and is headquartered in Panchkula, India.
1. Pharmaceutical Formulation-This segment manufactures and trades in medicines. It offers anti-cancer, anti-infective, neurology, emergency care medicine, skin and wound care, and pain management products.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Venus Remedies Ltd. | ₹1,929 Cr | 18.7 | 16.78% | ₹219 Cr | +239.1% |
Listed by market capitalisation. Ratios are shown for context only.
Venus Remedies Ltd. is trading at ₹1,500.00, with a market capitalisation of ₹1,929 Cr.
Venus Remedies Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Venus Remedies Ltd. has a P/E of 18.7 and a return on equity of 16.78%.
Venus Remedies Ltd. is listed on the BSE under the scrip code 526953.
Venus Remedies Ltd.'s share price is up 239.1% over one year and down 13.4% over three months. Its 52-week range is ₹441.75 to ₹2,044.30.
In Q2 FY27, Venus Remedies Ltd. reported revenue of ₹219 Cr and net profit of ₹26 Cr, with basic EPS of ₹19.19 (consolidated, parsed from the company's exchange filing).
Venus Remedies Ltd. reported revenue of ₹219 Cr in Q2 FY27, up 13.5% from ₹193 Cr in Q2 FY26 and up 22.3% from ₹179 Cr in Q1 FY27.
Promoters held 41.76% of Venus Remedies Ltd.'s shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.